Seeking Alpha

BioCryst Pharmaceuticals, Inc. (BCRX)

  • LaboMedic | Send Message 19 Feb

    $BCRX H.C. Wainwright Reiterates Bullish View On BioCryst Pharmaceuticals Following 4Q:14 Update
      • Clinically Sound Investor | Send Message 27 Jan

        Earnings Peek: BioCryst Pharmaceuticals Likely To Beat Estimates $BCRX
          • LaboMedic | Send Message 27 Jan

            $BCRX Roth Capital Reiterates Bullish Stance On BioCryst Pharmaceuticals Following FDA Fast-Track Status
              • Red Acre Investments | Send Message 31 Dec 2014

                Here's our December "report card" + forward looking comments on $BCRX $POZN $ABBV $VRTX $ACHN $BLUE $KITE
                  • LaboMedic | Send Message 23 Dec 2014

                    $BCRX BioCryst Pharmaceuticals: BCX4430 Non-Human Primate Data Is Encouraging, Says MLV
                      • LaboMedic | Send Message 22 Dec 2014

                        $BCRX MLV Reiterates Buy On BioCryst Following Rapivab FDA Approval
                          • The Desert Fox | Send Message 22 Dec 2014

                            $BCRX-FDA Approval for Rapivab!How much will it move???
                              • LaboMedic | Send Message 21 Dec 2014

                                Analyst Highlights - Week 51 - Healthcare (Part III) $BLRX $TTPH $ASPX $THLD $BCRX
                                  • Clinically Sound Investor | Send Message 18 Dec 2014

                                    The FDA May Find Some Use For Rapivab And Approve The Influenza Antiviral $BCRX
                                      • LaboMedic | Send Message 16 Dec 2014

                                        $BCRX Roth Capital Remains Bullish On BioCryst Pharmaceuticals Ahead Of OPuS-2 Initiation And Rapivab PDUFA
                                          Visit Seeking Alpha's
                                          BCRX vs. ETF Alternatives
                                          Company Description
                                          Biocryst Pharmaceuticals Inc. is engaged in the design, optimization and development of novel drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include Peramivir, BCX4161, Forodesine and Ulodesine, among others.
                                          Sector: Healthcare
                                          Industry: Biotechnology
                                          Country: United States